Author

Karanpreet Singh Bhatia

Emory UniversityORCID 0009-0001-9004-1257Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Ahmed M. MamdouhiD· 2 shared Chuqi WangiD· 2 shared Edward AyoubiD· 2 shared Fang Qi Lim· 2 shared Jordan Yong Ming TaniD· 2 shared Michael AndreeffiD· 2 shared Shruti BhattiD· 2 shared Xiao Xian LiniD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ahmed M. MamdouhORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 1, 2025

Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML)

Chuqi Wang, Yuhan Wang, Camillo Benetti…·Shruti Bhatt

This study identifies that macrophage-secreted pyrimidine metabolites confer chemotherapy resistance in AML by inhibiting drug activation, and shows that targeting macrophage metabolism can restore drug sensitivity.

1 citation

humanmetabolomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 17, 2025

BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia

Ahmed M. Mamdouh, Fang Qi Lim, Yang Mi…·Shruti Bhatt

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky